3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
3
Lymphoid
2
Tumor-Agnostic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Conditions
Recurrence
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
122
Cytarabine
112
fludarabine
91
fludarabine phosphate
80
Rituximab
75
Azacitidine
74
venetoclax
54
Methotrexate
52
Filgrastim
48
Whole-Body Irradiation
45
Busulfan
45
Tacrolimus
35
Etoposide
35
Mycophenolic Acid
34
Lenalidomide
32
Imatinib Mesylate
32
Antilymphocyte Serum
32
Granulocyte Colony-Stimulating Factor
31
Decitabine
31
Peripheral Blood Stem Cell Transplantation
29
Dexamethasone
29
Cyclosporine
29
Vincristine
26
Melphalan
26
Clofarabine
25
Alemtuzumab
25
Mitoxantrone
24
Stem Cell Transplantation
22
Radiotherapy
22
Dasatinib
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
parsaclisib
×
Other hematologic neoplasm
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts